fruquintinib + anti-pd-1 antibodies

Fruquintinib + anti-PD-1 antibodies is a combination therapy consisting of fruquintinib, an oral small-molecule inhibitor that selectively targets vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1/2/3), and an anti-programmed cell death protein 1 (PD-1) monoclonal antibody. Fruquintinib inhibits angiogenesis in tumors by blocking VEGFR signaling pathways. Anti-PD-1 antibodies (such as pembrolizumab, nivolumab, sintilimab, camrelizumab) are immune checkpoint inhibitors that block the PD-1 receptor on T cells to enhance antitumor immune responses. The combination aims to synergistically suppress tumor progression by both inhibiting tumor blood vessel formation and enhancing immune-mediated tumor cell killing. This regimen has shown clinical activity in patients with metastatic colorectal cancer (mCRC), particularly those with microsatellite-stable or proficient mismatch repair tumors who have progressed after standard therapies[1][2][4].

Brand names

Elunate

Other names

fruquintinib plus anti-PD-1fruquintinib and PD-1 inhibitorfruquintinib with anti-PD-1 antibody